Vusion is a drug owned by Mylan Pharmaceuticals Inc. It is protected by 1 US drug patent filed in 2013 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 30, 2028. Details of Vusion's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US8147852 | Modified azole compounds as antifungal and antibacterial agents |
Mar, 2028
(3 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Vusion's patents.
Latest Legal Activities on Vusion's Patents
Given below is the list of recent legal activities going on the following patents of Vusion.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 19 Sep, 2023 | US8147852 |
| Change in Power of Attorney (May Include Associate POA) Critical | 16 May, 2022 | US8147852 |
| Email Notification Critical | 16 May, 2022 | US8147852 |
| Correspondence Address Change Critical | 13 May, 2022 | US8147852 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 26 Sep, 2019 | US8147852 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 26 Sep, 2019 | US8147852 |
| Change in Power of Attorney (May Include Associate POA) Critical | 14 Nov, 2016 | US8147852 |
| Email Notification Critical | 14 Nov, 2016 | US8147852 |
| Correspondence Address Change Critical | 10 Nov, 2016 | US8147852 |
| Change in Power of Attorney (May Include Associate POA) Critical | 06 May, 2016 | US8147852 |
While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Vusion and ongoing litigations to help you estimate the early arrival of Vusion generic.
Vusion's Litigations
Vusion been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Nov 15, 2010, against patent number US8147852. The petitioner , challenged the validity of this patent, with Marcel Borgers et al as the respondent. Click below to track the latest information on how companies are challenging Vusion's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US8147852 | November, 2010 |
Decision
(08 Aug, 2011) | Marcel Borgers et al | |
US patents provide insights into the exclusivity only within the United States, but Vusion is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Vusion's family patents as well as insights into ongoing legal events on those patents.
Vusion's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Vusion's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 30, 2028 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Vusion Generics:
There are no approved generic versions for Vusion as of now.
About Vusion
Vusion is a drug owned by Mylan Pharmaceuticals Inc. It is used for treating diaper dermatitis complicated by candidiasis. Vusion uses Miconazole Nitrate; White Petrolatum; Zinc Oxide as an active ingredient. Vusion was launched by Mylan in 2006.
Approval Date:
Vusion was approved by FDA for market use on 16 February, 2006.
Active Ingredient:
Vusion uses Miconazole Nitrate; White Petrolatum; Zinc Oxide as the active ingredient. Check out other Drugs and Companies using Miconazole Nitrate; White Petrolatum; Zinc Oxide ingredient
Treatment:
Vusion is used for treating diaper dermatitis complicated by candidiasis.
Dosage:
Vusion is available in ointment form for topical use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.25%;81.35%;15% | OINTMENT | Prescription | TOPICAL |